Alamar Biosciences, Inc. ALMR
26.46 USD -2.22 (-7.74%)
As ofNov 20, 2026, 2:31 PM EST
26.41 Day range 28.22
18.85 52-week range 39.61
- YTD
- +20.27%
- 1 year
- +20.27%
News
benzinga.com Alamar Biosciences Announces New Research Published In JAMA That Uses Its NULISAqpcr eMTBR-Tau Single-Plex Assay To Evaluate Whether A Blood Test Could Identify CTE In Living Patients New research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used…
globenewswire.com JAMA Study Using Alamar Biosciences' NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE FREMONT, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced…
globenewswire.com Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived p-tau217 testing and expand…benzinga.com TD Cowen Maintains Buy on Alamar Biosciences, Raises Price Target to $36 TD Cowen analyst Dan Brennan maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $34 to $36.
benzinga.com Alamar Biosciences Q3 2026 Earnings Call Transcript Alamar Biosciences (NASDAQ:ALMR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Alamar Biosciences Raises FY2026 Sales Guidance from $116.000M-$120.000M to $121.000M-$123.000M vs $118.632M Est Alamar Biosciences (NASDAQ:ALMR) raises FY2026 sales outlook from $116.000 million-$120.000 million to $121.000 million-$123.000 million vs $118.632 million estimate.
benzinga.com Alamar Biosciences Q3 EPS $(0.19); Sales $33.55M Up 68% From $19.91M YoY Alamar Biosciences (NASDAQ:ALMR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. The company reported quarterly sales of $33.550…
benzinga.com Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc…
